Targeting FOXO3 for the Management of Heart Failure: Current Evidence and Future Directions
See-Hyoung Park · 2026
Read Targeting FOXO3 for the Management of Heart Failure: Current Evidence and Future Directions by See-Hyoung Park (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13610271.txt.
Description
See-Hyoung Park reviews a longevity-linked protein as a heart failure target in a 2026 paper. The transcription factor FOXO3 steers cell defenses against oxidative stress, cell death, self-digestion, and inflammation. When its control slips, heart failure worsens, which makes it an attractive drug target.
Park surveys FOXO3-modulating compounds studied between 2006 and 2026, from plant chemicals to pharmaceuticals, and the pathways through which they act. In animal and cell models many improved heart function. Yet translation to patients remains the weak point, and the review names the field's method limits plainly. It closes with directions for better experiments, aiming to move FOXO3 from a promising switch to a tested therapy.
Catalog record
| CREATOR | See-Hyoung Park |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |